Insmed (NASDAQ:INSM) CEO William Lewis Sells 10,699 Shares

Insmed, Inc. (NASDAQ:INSM) CEO William Lewis sold 10,699 shares of the firm’s stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $158.93, for a total value of $1,700,392.07. Following the transaction, the chief executive officer owned 306,891 shares in the company, valued at approximately $48,774,186.63. This trade represents a 3.37% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

William Lewis also recently made the following trade(s):

• On Monday, January 12th, William Lewis sold 19,215 shares of Insmed stock. The shares were sold at an average price of $169.00, for a total value of $3,247,335.00.
• On Thursday, January 8th, William Lewis sold 3,223 shares of Insmed stock. The shares were sold at an average price of $174.17, for a total value of $561,349.91.
• On Wednesday, January 7th, William Lewis sold 2,357 shares of Insmed stock. The stock was sold at an average price of $175.07, for a total transaction of $412,639.99.
• On Tuesday, January 6th, William Lewis sold 4,096 shares of Insmed stock. The stock was sold at an average price of $173.33, for a total transaction of $709,959.68.
• On Thursday, December 18th, William Lewis sold 10,699 shares of Insmed stock. The shares were sold at an average price of $166.97, for a total value of $1,786,412.03.

Insmed Trading Up 2.6%

Shares of Insmed stock opened at $160.39 on Friday. The stock has a market capitalization of $34.21 billion, a P/E ratio of -25.91 and a beta of 1.08. Insmed, Inc. has a 52-week low of $60.40 and a 52-week high of $212.75. The company has a debt-to-equity ratio of 0.59, a quick ratio of 4.34 and a current ratio of 4.63. The stock’s 50-day simple moving average is $185.14 and its 200 day simple moving average is $155.69.

Insmed (NASDAQ:INSM) last posted its earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.35) by ($0.40). Insmed had a negative return on equity of 183.55% and a negative net margin of 264.83%.The company had revenue of $142.34 million for the quarter, compared to analysts’ expectations of $114.33 million. During the same quarter in the prior year, the company earned ($1.27) EPS. The company’s revenue was up 52.4% on a year-over-year basis. As a group, research analysts anticipate that Insmed, Inc. will post -4.56 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. CIBC Private Wealth Group LLC lifted its holdings in shares of Insmed by 42.1% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 53 shares during the last quarter. CoreCap Advisors LLC bought a new stake in Insmed in the fourth quarter worth $27,000. ORG Partners LLC boosted its position in Insmed by 220.2% during the second quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 196 shares during the period. Hilltop National Bank bought a new position in shares of Insmed during the second quarter valued at about $28,000. Finally, Stone House Investment Management LLC purchased a new position in shares of Insmed in the third quarter worth about $29,000.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. Royal Bank Of Canada boosted their price target on shares of Insmed from $197.00 to $200.00 and gave the company an “outperform” rating in a research report on Wednesday. Roth Mkm began coverage on Insmed in a research note on Thursday. They set a “buy” rating and a $212.00 price objective for the company. Rothschild & Co Redburn assumed coverage on Insmed in a research note on Thursday, December 4th. They issued a “buy” rating and a $263.00 target price on the stock. Guggenheim lowered their price target on Insmed from $230.00 to $221.00 and set a “buy” rating on the stock in a report on Thursday, December 18th. Finally, Wolfe Research set a $167.00 price objective on Insmed and gave the stock an “outperform” rating in a report on Thursday, December 18th. Two analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $204.68.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.